Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115066) titled 'A Multicenter, Randomized, Double-Blind, Placebo-Controlled Parallel-Group Phase III Clinical Trial of Hepalatide for Injection in Patients with Chronic Hepatitis D' on Dec. 22, 2025.
Study Type: Interventional study
Study Design:
Parallel
Primary Sponsor: Jilin University First Hospital
Condition:
Chronic hepatitis D
Intervention:
L47 2.1mg Group:L47 2.1mg QD+ ETV 0.5mg QD
Recruitment Status: Not Recruiting
Phase: 3
Date of First Enrollment: 2026-02-01
Target Sample Size: L47 2.1mg Group:100;Placebo Group:50;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj....